DE | EN
Navilas OD-OS GmbH
Warthestr. 21
14513 Teltow

TEL +49 (0)3328 31282 100
FAX +49 (0)3328 31282 999

info@od-os.com
http://www.od-os.com


Navilas® Laser System — Wirksam und komfortabel behandeln mit Navigation


Navilas® 577s ist ein vollständig digitales System zur fokalen/panretinalen Photokoagulation, das die Behandlung Visus bedrohender Netzhauterkrankungen (u. a. diabetisches Makulaödem, proliferative diabetische Retinopathie, Retinopathia centralis serosa und Netzhautvenenverschluss) revolutioniert.


Mit dem Ziel einer wirksameren Behandlung bietet Navilas® erstmals eine exakte Planung auf verschiedenen Diagnostikbildern mit präziser, computergestützter Ausführung und digitaler Dokumentation. Die Möglichkeit der Behandlung ohne Kontaktglas und unter Infrarotbeleuchtung bietet einen hohen Komfort für Patienten und Ärzte. 

 

Für eine besonders gewebeschonende Behandlung ist ein spezieller navigierter Mikrosekundenpuls-Modus verfügbar.

 

Ein optimiertes Therapiekonzept hat es zum Ziel, pharmakologische Therapien länger wirksam und kosteneffektiver zu machen.


Weitere Informationen: www.od-os.com

 

 NAVILAS OD-OS.png (221 KB)

 

Über OD-OS GmbH


Im Jahr 2008 in Teltow bei Berlin gegründet, hat sich die OD-OS GmbH zum Ziel gesetzt, die Netzthauttherapie mit der Retina Navigation und dem Navilas® Laser System zu revolutionieren.

 

 

 

 

 

 

 

Navilas® Laser System — Effective and comfortable treatment with navigation


Navilas® 577s is an all-digital, advanced focal/panretinal photocoagulation device designed for the treatment of vision-threatening retinal diseases such as Diabetic Macular Edema, Proliferative Diabetic Retinopathy, Retinal Vein Occlusions, and Central Serous Chorioretinopathy.


Designed for higher efficacy, Navilas® delivers precise treatment planning on different diagnostic images, computer-assisted laser delivery, and digital documentation. The possibility to perform focal treatments under infrared light and without a contact lens, makes treatment much more comfortable for patients and doctors. 

 

For a tissue-friendly treatment, a special navigated microsecond pulse mode is available.

 

An optimized therapy concept aims at adding a durable effect and cost-effectiveness to pharmacological therapies.


More information: www.od-os.com

 NAVILAS OD-OS.png (221 KB)

 

About OD-OS GmbH


Founded in 2008 in Teltow near Berlin, OD-OS GmbH aims to revolutionize retinal therapy with Retina Navigation and the Navilas® Laser System.


Unternehmensnachrichten

AAO 2018: Non-contact Panretinal Photocoagulation for Navilas® 577s Introduced24.10.2018

First retinal laser with a navigated non-contact treatment option for panretinal photocoagulation up to the far periphery.
Visit AAO booth #740 for a demo of enhanced comfort for sensitive patients.

                  

Just in time for the Annual Meeting of the American Academy of Ophthalmology (AAO 2018) in Chicago, OD-OS is launching a new widefield objective which brings non-contact panretinal photocoagulation with access to the far periphery (ora serrata) to the Navilas® 577s Laser System. The new option for peripheral treatments can further enhance compliance of sensitive patients and therefore allow for more comfortable PRP sessions.

This addition makes Navilas® the only retinal laser which allows for navigated focal and peripheral treatments (single spots and pattern) without a contact lens. The system supports digital pre-planning and computer-assisted delivery of laser spots thanks to its integrated eye tracking technology.

For a demo of navigated non-contact PRP treatment, visit OD-OS at the AAO in Chicago:
- October 26: #44 at the AAO Retina Subspecialty Day 
- October 27-30: #740 at the AAO main exhibition

The non-contact widefield objective will become available to Navilas® 577s users at the end of this year. 
Regional availability may vary. 

Here is what Navilas® users, who recently tested the non-contact widefield objective in clinical practice are saying:

Dr. Gregor Eberlein, University Clinic Augsburg, Germany: “My experience of extending comfortable non-contact treatment to the periphery was really good. It can be a great option for retinopexy and PRP treatments of patients averse to the contact lens.”

Dr. Jean-Christophe Ramel, France: “The field of view of the non-contact widefield objective is really amazing. I had a perfect view of a retinal tear in the far periphery.”

Dr. Stephan Deichelbohrer, St. Vincentius-Kliniken Karlsruhe, Germany: “The non-contact widefield objective allows me to apply more spots in a single session as the cornea remains clear throughout the whole procedure – also by letting the patient lean back and blink for a moment. When using a standard contact lens the image quality may degrade due to superficial staining of the cornea.”

Ulrike Rahn, Clinical Project Manager at OD-OS: “This is a result from a successful collaboration with our Navilas® customers at CHI de Créteil in France that our development team has now turned into another treatment option for our Navilas® 577s Laser.” 

Listen to Navilas® users at AAO: 
- Q&A sessions at OD-OS #740 on October 27/28 at 10:00 am – more at: www.od-os.com/aao2018
- Talk by our user Dr. Jay Chhablani at Retina Subspecialty Day covering current knowledge on microsecond pulsing laser treatment (RET07, Friday, Oct 26, 11:39 am, Room: ARIE CROWN)

About Navilas®:  Navilas® laser systems enable physicians to digitally pre-plan the entire laser therapy on fundus images as well as on third-party diagnostic images, and to precisely execute this therapy plan with the help of computerized image guidance.

About OD-OS: OD-OS GmbH is a privately-held medical device company founded in 2008 with offices in Teltow, Germany, and Irvine, CA. www.od-os.com

For further information, please contact:
Stefanie Gehrke, Director Marketing | stefanie.gehrke@od-os.com, +49 (172) 3808 537
OD-OS GmbH | Warthestr. 21 | 14513 Teltow | German

Navilas® 577s is the first retinal laser with a navigated non-contact treatment option for panretinal photocoagulation up to the far 

At EURETINA 2018, Navigated Retina Laser is Moving into the Next Decade20.09.2018

10 years of Navilas® – Renowned customer community brings the benefits of retina navigation to applications beyond DME. All-digital platform supports subthreshold treatments, digital collaboration, standardization, and learning in retina care.

19 Sep 2018

OD-OS, the inventor of the Navilas® laser systems, celebrates 10 years of retina navigation with expert sessions at the upcoming EURETINA 2018 conference (Vienna, Sep 21-25, booth C207).

Navilas® has brought digital pre-planning and precise and fast computer-assisted delivery of laser spots to focal and peripheral laser treatment - with the option to plan and treat on external diagnostic images such as OCT-A or FA. Today, Navilas® is being used in more than 25 countries worldwide including the ten countries with the highest gross income. Private practices and renowned hospitals like the New York Eye and Ear Infirmary (USA), the Nagoya City University Hospital (Japan), the University Clinics of Tübingen and Freiburg, and the Ludwig-Maximilians-University (LMU) Munich (Germany) are working with Navilas® to provide enduring results and reduce treatment burden for their patients (1).

Thanks to contributions from this global customer community and the success of the compact Navilas® 577s system, effective and comfortable treatment with navigated retina laser is now expanding into applications beyond DME (1). At the same time, the all-digital platform is incorporating trends such as subthreshold microsecond pulsing therapy and telemedicine, thus supporting digital collaboration, standardization and learning in retina care.

Prof. Eric Souied of CHI de Créteil, France, elected for the 2018 Power List of the top ophthalmologists worldwide, says: “Navilas® provides the digital functionality and safety to explore optimal treatment strategies in a range of retinal indications. Our patients especially value the possibility of contact-free focal treatments.”

His colleague Dr. Alexandre Pedinielli adds: ”Therefore, we are excited that at EURETINA OD-OS presents the result of a close collaboration with our team – the demonstrator of a new widefield objective which can make non-contact panretinal photocoagulation with access to the extreme periphery a treatment option for experienced Navilas® 577s users. We are looking forward to seeing more clinical data from this solution in practice. We really believe that this could be an important step towards the future of PRP as an almost completely harmless procedure for the patient.“

“In the last decade, we have brought the latest computer vision technology to our retina navigation platform,” says Dr. Winfried Teiwes, Managing Director at OD-OS GmbH. “Feedback from users and patients is now helping us extend the Navilas® treatment approach to new retina applications like CSCR, which require a precise, effective and tissue-friendly retina laser.”

“The next decade is also seeing new concepts and functionalities to be added thanks to advances in computer vision technology. One important step is to make the treatment planning functionality of our retina laser accessible in the cloud. Thus, we are moving step by step towards more efficient workflows, and a pool of online knowledge which brings expertise resources to underserved areas and benefits efforts to standardize treatment approaches.”

At the EURETINA 2018 conference in Vienna, retina specialists will present their clinical experiences with the all-digital Navilas® laser. Cases cover a range of applications from Proliferative Diabetic Retinopathy to Central Serous Chorioretinopathy – with a special focus on navigated microsecond pulsing treatment results.

Meet the expert presentations will be held Friday through Sunday at 10:00 am at the OD-OS Navilas® booth C207. Official program sessions on Navilas® include a talk by Dr. F. Amoroso, CHI de Créteil (Friday, Sep 21, 11:00 am-12:30 pm, Room C2) which covers experiences with the demonstrator of the widefield objective for non-contact PRP treatment with Navilas®.

A list of all Navilas® related Euretina sessions is available at: https://www.od-os.com/events/detail/sep-20-26-2018-euretinaescrs-vienna-austria/

(1) www.od-os.com/publications

About Navilas®: Navilas® laser systems enable physicians to digitally pre-plan the entire laser therapy on fundus images as well as on third-party diagnostic images, and to precisely execute this therapy plan with the help of computerized image guidance.

eyefox-unternehmens-nachrichten-navilas-achsenlaenge-csm.jpg (26 KB)
At EURETINA 2018, OD-OS presents the demonstrator of a new widefield objective for non-contact PRP treatment to be performed by experienced Navilas® users. The tool results from a successful customer collaboration with Dr. A. Pedinielli and Dr. F. Amoroso (pictured) of the team around Prof. Eric Souied at CHI de Créteil in France.

Neue Website informiert Diabetiker über die navigierte Laserbehandlung von Netzhauterkrankungen13.08.2018

28 Feb 2018 - Das Augenlicht erhalten: Neue Website informiert Diabetiker über die navigierte Laserbehandlung von Netzhauterkrankungen


Die neue Internetplattform www.navilas.de informiert Diabetiker und deren Angehörige verständlich über das Augenlicht bedrohende Netzhauterkrankungen, die Notwendigkeit von Vorsorgeuntersuchungen und verbesserte Behandlungsmöglichkeiten mit moderner, navigierter Lasertherapie.

Navilas® ist der einzige digitale Netzhautlaser, welcher sich der modernen Eye-tracking-Technologie bedient. Die Vorteile für Patienten: Eine effektive Behandlung zum Erhalt der Sehfähigkeit mit weniger Schmerzen1 und weniger Nachbehandlungen

OD-OS Achieves Revocation of Iridex MicroPulse Patent and Clears Path to Tissue-Friendly Treatment with Navilas® in Clinical Practice23.07.2018

OD-OS Achieves Revocation of Iridex MicroPulse Patent and Clears Path to Tissue-Friendly Treatment with Navilas® in Clinical Practice

 

 

The Navilas® Laser System makes tissue-sparing treatment of retinal diseases more predictable, and paves the way for widespread adoption of microsecond pulse protocols in standard clinical practice.

 

16 Jul 2018

OD-OS, the global leader in the development and commercialization of navigated retinal laser systems, has achieved the revocation of the MicroPulse™ Patent (Patent no EP1856774) by Iridex Cooperation in oral proceedings at the European Patent office held last Friday in Munich, Germany.

With its successful opposition, OD-OS has cleared the path to manufacture and market its Navilas® Laser System with microsecond pulsing technology. Navilas® features computer-assisted laser delivery and digital documentation, thus making subthreshold treatment of retinal diseases more predictable, and easier to reproduce in standard clinical practice.

The technology of using laser pulses down to 25 microseconds for retinal care has been introduced and marketed by Iridex as MicroPulse™ laser. MicroPulse™ is a trademark of Iridex Corporation.

Winfried Teiwes, Managing Director, OD-OS GmbH: “We fully respect the effort Iridex Cooperation has put into the clinical development how tissue-sparing, shorter laser pulses can be effective for retinal treatments. With Navilas®, we are providing a contact free, easy to use and transparent delivery technique of these laser pulses, which allows standardized treatment protocols. We will work with Navilas® users to make microsecond pulse treatment a non-contact, non-damaging but long-lasting treatment in clinical practice, and a viable addition to often chronical injections.”

Several studies have presented recent evidence on the effectiveness of navigated microsecond pulsing with Navilas®, e.g. for treating focal leakage in chronic central serous chorioretinopathy (www.od-os.com/publications). 

Main benefits of tissue-friendly treatment with the Navilas® Laser System:

  • Image-guided, pre-planned laser delivery allows for systematic application of confluent laser pattern without overheating through adjacent spot delivery, which avoids overlapping application of laser pulses. 
  • Digital documentation enables users to develop a simplified treatment parameter set that can be applied in standard clinical practice.
  • Non-contact application of microsecond pulses with Navilas® makes this treatment very comfortable for patients and easy to apply for users.

About Navilas®Navilas® laser systems enable physicians to digitally pre-plan the entire laser therapy on fundus images as well as on third-party diagnostic images, and to precisely execute this therapy plan with the help of computerized image guidance.

About OD-OS: OD-OS GmbH is a privately-held medical device company founded in 2008 with offices in Teltow, Germany, and Irvine, CA. www.od-os.com

For further information, please contact: Stefanie Gehrke, Director Marketing | stefanie.gehrke@od-os.com, +49 (172) 3808 537 OD-OS GmbH | Warthestr. 21 | 14513 Teltow | Germany 

Welcome to the age of smart laser26.09.2016

Welcome to the age of smart laser:   

Das revolutionäre Navilas® Laser System 577s

 

Pünktlich zum DOG Kongress ab dem 29.09.2016 in Berlin, gibt die OD-OS GmbH heute die offizielle Produkteinführung des kompakten, navigierten Netzhautlasers Navilas® 577s auf dem deutschen Markt bekannt.

 

Für eine wirksamere Netzhautbehandlung erlaubt Navilas®, als erster vollständig digitaler Laser, eine exakte Planung mit präziserer komfortablerer Ausführung.

 

Gegenüber dem Flaggschiff-Produkt Navilas 577+ ist Navilas 577s deutlich kompakter und für die intuitive Anwendung gestaltet. Navilas 577s überführt die navigierte Lasertherapie damit endgültig in die klinische Routine.

Besuchen Sie uns auf der DOG. Unser Team freut sich auf Sie!

Weitere Informationen dazu finden Sie auf: www.od-os.com

Press release hier herunterladen: Das revolutionäre Navilas® Laser System 577s

 

 

Der navigierte Netzhautlaser 577s von Navilas

Wirtschaftsminister zu Besuch bei OD-OS15.01.2016

Bild Navilas - Wirtschaftsminister zu Besuch bei OD-OSWirtschafts- und Energieminister Albrecht Gerber informierte sich über die navigierte Netzhaut-Lasertherapie mit Navilas® bei der OD-OS GmbH in Teltow

 

Teltow – 11. Januar 2016

 

 

 

 

OD-OS, das weltweit führende Unternehmen in der navigierten Netzhaut-Laserbehandlung Sehkraft bedrohender Augenerkrankungen konnte am 11. Januar Brandenburgs Minister für Wirtschaft und Energie Herrn Minister Albrecht Gerber und Herrn Sören Kosanke MdL in Teltow begrüßen. Geschäftsführer Herr Dr. Teiwes stellte ihnen das Unternehmen und seine Technologie vor.


Die Besichtigung begann mit einer Vorstellung des einzigartigen Produktes von OD-OS, dem navigierten Lasers Navilas®, gefolgt von eingehender Diskussion über Chancen und Herausforderungen für innovative Medizintechnikunternehmen in Brandenburg und anschließenden simulierten Behandlung mit dem präzisen, sicher und einfach anzuwendenden Laser Navilas®.

 

Minister Gerber zeigte sich beeindruckt über den medizinischen Fortschritt, repräsentiert durch innovative Brandenburger Produkte wie dem navigierten Laser Navilas® „Navilas® ist ein weiteres Beispiel für die Innovationskraft im Land, die immer wieder Weltmarktführer hervorzubringen vermag. Wir sind gespannt auf die weitere Entwicklung der OD-OS GmbH, ihrem Eintritt in neue Märkte in Asien und Lateinamerika und der Ausweitung der Geschäftstätigkeit im deutschsprachigen Raum. Wir wünschen der OD-OS GmbH viel Erfolg.“

 

Dr. Winfried Teiwes, Geschäftsführer der OD-OS GmbH ergänzte dazu: „Wir freuen über das Interesse des Ministers Gerber und des Landtagsabgeordneten Herrn Kosanke an innovativer Medizintechnik. Mit Unterstützung durch das Land Brandenburg konnten wir den einzigartigen navigierten Laser entwickeln und Patienten weltweit zugänglich machen – hierfür danken wir dem Land sehr herzlich. Für die Patienten ist die präzisere Laserbehandlung mit dem Navilas deutlich effektiver und nachhaltiger  als mit bisherigen Lasersystemen und zudem angenehmer. Insbesondere diabetischen Augenpatienten kann damit so manche unangenehme und kostenintensive Medikamenteninjektion in den Augapfel erspart werden. Auf unserer Wunschliste stünde die weitere Unterstützung des Ministeriums im Dialog mit den Krankenkassen, die zusätzlich zu den Patienten von deutlich reduzierten Kosten profitierten. Von Berlin-Lichterfelde bis Japan gibt es überzeugte Anwender der navigierten Lasertherapie- wir würden uns freuen, wenn wir bald das erste Gerät in Brandenburg aufstellen könnten.“